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Background: Most lung cancer patients are diagnosed with advanced 
disease, underscoring the need of early diagnosis. To date, there is no 
known clinically useful blood-based biomarker for lung cancers. Nev-
ertheless protein based biomarkers in the blood hold a great promise as 
diagnostic markers for disease states and outcomes in clinical cancer 
management.
We hypothesize that tumor cells and the reactive host stroma secrete 
several speciﬁc proteins that can be readily detected by methods more 
sensitive than the presently available clinical methods. Furthermore, ra-
diation and chemotherapy treatments can cause tumor lysis and release 
of intracellular proteins that can be detected in the blood with a highly 
sensitive approach and the level of such proteins can provide immedi-
ate response information for clinical decision. 
Methods: Multiplexed and sensitive detection technologies with low 
sample consumption are required for validating large sets of biomarker 
candidates. Conventional immunoassays are hampered by limited 
sensitivity and relative high sample consumption. Our group has de-
veloped a new method named proximity ligation assay that is based on 
PCR-methods for protein analysis. In short, the assay employs a pair of 
proximity probes each composed of an antibody linked to an oligo-
nucleotide. As these two antibody-based probes bind the protein analyte 
in solution, the two corresponding oligonucleotides gain a signiﬁcant 
increase in local concentration. This enables the hybridization of a 
connecting oligonucleotide, leading to the formation of a unique target 
reporter amplicon that is quantiﬁed by real-time PCR. Several proteins 
(seven in each assay-set) are analyzed in one parallel reaction, and 
levels of different proteins are standardized against a known amount of 
controlled added protein. Each 7-plex assay requires only one microliter 
of either plasma or serum. When compared to standard ELISA meth-
odology, the detection limits of the described method are up to three 
orders of magnitude lower (Fredriksson et al, Nature Methods in press).
Results: We have generated antibody-oligonucleotide set for 27 can-
didate proteins to be used in our assays. These include markers of hy-
poxia (osteopontin, HIF1), growth factors and cytokines (PDGF, IGF-2, 
CTGF, VEGF, MIF, TNFa, IL4, IL7, IL10), oncogenes and known 
tumor markers (erb-B2, CEA, CA125, CA19-9), extracellularly active 
molecules (ADAM8, SLPI, galectin 1, mesothelin, EpCam) and others.
Preliminary results indicate the feasibility and sensitivity of the 
method, and complete results on all markers will be presented. 
Conclusion: We have successfully generated several new antibody-
oligonucleotide sets for candidate serum markers. We have shown 
that it is feasible to detect these proteins in NSCLC patient blood and 
that PLA was more sensitive than conventional ELISA in detecting 
a subset of markers. Future directions will focus on generating more 
antibody-oligonucleotide sets for new proteins, speciﬁcally those that 
are induced in NSCLC in gene-expression datasets. In addition, we 
will apply this method to a larger set of serum samples from NSCLC 
patients and matched healthy controls to identify a diagnostic circulat-
ing protein signature for NSCLC.
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Background: We have demonstrated through an analysis of SEER data 
on 307,797 lung cancer patients diagnosed between 1975 and 2003 
that adenocarcinoma of the lung is now the most common form of lung 
cancer in the US. Indeed, adenocarcinoma is currently the most com-
mon histologic subtype of lung cancer in both women and men, blacks 
and whites, and in all age groups. The objective of this analysis is to 
examine relative survival in relation to histologic subtype. 
Methods: SEER data on 234,273 lung cancer patients diagnosed in the 
US between 1980 and 2002 were analyzed. The primary endpoint was 
ﬁve-year survival of the four major lung cancer histologies: adenocar-
cinoma, squamous cell carcinoma, small cell carcinoma, and large-cell 
carcinoma. Five-year survival was measured for patients diagnosed 
during four time intervals (1980-1984, 1985-1989, 1990-1994, 1995-
2002). Comparisons were drawn based upon stage (localized, regional, 
and distant) gender, race (white versus black) and age group (<40-yrs; 
40-49-yrs, 50-59-yrs, 60-69-yrs, 70-79-yrs, >80-yrs). 
Results: Stage of disease was clearly the most powerful predictor of 
ﬁve-year survival. However, histologic subtype was also a major pre-
dictor of survival. When all stages are combined, survival was highly 
statistically signiﬁcantly superior in adenocarcinoma compared to other 
histologies (p<0.0001). Among patients with localized disease, 5-year 
survival in adenocarcinoma was far superior to that of squamous cell 
carcinoma, the second most favorable histology. For example, for cases 
diagnosed in 1995-2002, 5-year survival for localized disease was 
60.1% for adenocarcinoma, 44.2% for squamous cell, 41.3% for large 
cell and 20.1% for small cell carcinoma. Interestingly, ﬁve-year sur-
vival within histologic subgroups has improved very little over this 22-
year period. For example, 5-year survival for localized adenocarcinoma 
of the lung in 1980-1984 was 58.3% compared to 60.1% in 1995-2002. 
Among patients with regional disease, 5-year survival for adenocar-
cinoma was slightly better than the other histologies. For cases with 
regional disease diagnosed from 1995-2002, ﬁve-year survival was 
20.1% for adenocarcinoma, 16.3% for squamous cell, 15.9% for large 
cell and 10.7% for small-cell. Signiﬁcantly superior survival in adeno-
carcinoma was probably related to more favorable stage distribution 
in adenocarcinoma. For example, 38.2% of adenocarcinoma patients 
had localized disease compared to 25.2% of squamous cell patients 
(p<0.0001). Among those with distant disease, ﬁve-year survival was 
approximately 2% for all histologies. Overall, when adjusted for stage 
and histology, 5-year survival was signiﬁcantly superior in females 
compared to males. However, the survival advantage was most striking 
for women with localized adenocarcinoma. When comparing blacks to 
whites, survival was inferior for blacks, when adjustments were made 
for stage and histology. For those diagnosed between 1995-2002, sur-
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vival for blacks and whites with localized adenocarcinoma was 52.0% 
and 60.6%, while survival was 44.5% and 41.5% for blacks and whites 
with squamous cell carcinoma, respectively. With regard to age group 
comparisons, there was a signiﬁcant decrease in 5-year survival with 
advancing age among those with localized disease.
Conclusions: Differences in relative survival of lung cancer was 
strongly dependent upon histologic subtype. Indeed, ﬁve-year survival 
for adenocarcinoma of the lung is signiﬁcantly superior to that of other 
histologic subtypes. Improved survival in adenocarcinoma appears to 
be related to a more favorable stage distribution, which facilitates cura-
tive therapies
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Background: Sputum methylation analysis is feasible and by some 
studies suggested to show an increased risk for lung cancer. The aim of 
this study was to examine 6 methylation markers in sputum of patients 
with lung cancer and controls.
Methods: In the Canisius Wilhelmina Hospital Nijmegen sputum has 
been prospectively collected for several years of patients with lung 
cancer and controls. From this bank 102 cases with lung cancer and 
102 controls, most of them with COPD DNA was retrospectively 
extracted. Samples were subsequently randomized and blinded (TdB). 
Coded samples were exchanged between collaborators unaware of its 
origin. Quantitative MSP was performed for APC, Cytoglobin, MGMT, 
3-OST-2, p16, RASSF1A, and TCF21. Follow-up was retrieved inde-
pendently (MvdD). Pathology diagnosis was based on biopsy or only 
cytology. After submission of methylation data (to ZF with subsequent 
information of TdB) statistical analysis was performed (WY,ZF). 
Results: The pathology diagnosis was squamous cell carcinoma 
(n=23), adenocarcinoma (n=23), SCLC (n=16) or NSCLC not further 
speciﬁed. The 77 of the 102 controls had a Gold score for COPD >0. 
Sputum samples were collected within 6 months of lung cancer diagno-
sis. Follow-up of COPD cases was minimally 2 years.
Reproducibility of methylation analysis between two labs was poor for 
MGMT.
RASSF1A showed hypermethylation in 81 % of the SCLC and 69% of 
the NSCLC lung cancer cases with a speciﬁcity of 94 and 74%, respec-
tively. For two markers the sensitivity showed a decrease in sensitivity 
for SCLC and NSCLC to 50%, and 57%, respectively. The speciﬁcity 
increased for SCLC and NSCLC to 99 and 95%, respectively.
Conclusions: This blinded study shows that hypermethylation in spu-
tum is with two markers detects 50% of the lung cancer patients.
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Background: Concurrent chemoradiation is standard treatment for 
pts with inoperable stage III NSCLC. A previously reported single-
arm, phase II study by SWOG (Gandara et al JCO 2003) suggested D 
following EP/XRT further improved survival. We report results from 
a randomized, prospective phase III trial comparing EP/XRT with or 
without consolidation D.
Methods: Eligible pts had inoperable, stage IIIA/B NSCLC, PS 0-1 at 
study entry, FEV-1 > 1 L, and < 5% wt loss in the preceding 3 mos. Pts 
(n=243) received P 50 mg/m2 iv d 1,8,29,36 and E 50 mg/m2 iv d1-5, 
29-33 concurrently with chest XRT to 5940 cGy. Non-progressing pts 
(PS 0-2) were randomized to D 75 mg/m2 iv every 21 d for 3 cycles vs 
observation (O). The primary endpoint was to compare OS (Kaplan-
Meier analysis). A multivariate parametric accelerated failure time 
model was performed to identify factors that affected survival. Accrual 
of 259 pts to randomize 180 was planned to demonstrate a difference 
in MST of 25 vs 15 mos (5% 2-sided alpha, 80% power). Based upon 
evidence of futility (predeﬁned as p>0.7271), a DSMB recommended 
early termination after an analysis of the initial 203 pts. 
Results: Median f/u 25.6 mos. Pt characteristics (n=203): 34%/66% F:
M; median age 63; 39.4%/60.6% IIIA/B; staged with PET 66.5%; FEV-
1 > 2 46.7%; current smoker 41.9%. G3/4 toxicities during EP/XRT 
included 9.8% febrile neutropenia (FN), 17.2% esophagitis. 147 of 
203 pts (72.4%) were randomized to D (n=73) or O (n=74). 82.2% 
randomized to D received 3 cycles. G3/4 toxicities during D included: 
10.9% FN, 8.2% pneumonitis. 28.8% of pts were hospitalized during D 
(vs 8.1% in O arm) and 5.5% died due to D. Factors predictive for im-
proved survival included age < 70, FEV-1 > 2, and hemoglobin > 12 at 
baseline. PFS for D was 12.3 vs 12.9 mos for O (p=0.9412). The MST 
for all pts (n=203) was 21.15 mos; MST for D was 21.6 mos (95% C.I. 
17.7-35) vs 24.2 mos for O (95% C.I. 18.1-34.4) (p=0.9402). 
Conclusions: The MST with EP/XRT was higher than historical 
controls; however, consolidation D does not further improve survival, 
is associated with signiﬁcant toxicity including an increased rate of 
hospitalization and premature death.
